Feedback / Questions
Kisqali (ribociclib) - Novartis
Kisqali: Regulatory submission for HR+, HER2(-) breast cancer (adjuvant) in 2023 or later
(Novartis)
-
Oct 22, 2019 -
Q3 2019 Results
Regulatory
https://www.novartis.com/sites/www.novartis.com/files/q3-2019-ir-presentation.pdf
Oct 22, 2019
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious